title: Development, evaluation, and application of an in silico model for antimalarial drug treatment and failure.
abstract: Pharmacological mechanism-based modeling was refined and used to develop an in silico model of antimalarial drug treatment validated against clinical and field data. We used this approach to investigate key features of antimalarial drug action and effectiveness, with emphasis on the current generation of artemisinin combination therapies. We made the following conclusions. (i) The development of artemisinin tolerance and resistance will, unless checked, have an immediate, large impact on the protection afforded to its partner drug and on the likely clinical efficacy of artemisinin combination therapies. (ii) Long follow-up periods are required in clinical trials to detect all drug failures; the follow-up periods of 28 days recommended by the World Health Organization are likely to miss at least 50% of drug failures, and we confirmed recent suggestions that 63 days would be a more appropriate follow-up period. (iii) Day 7 serum drug concentrations are a significant risk factor of failure, although, paradoxically, receiver operating characteristic curve analysis revealed that their predictive power is relatively poor. (iv) The pharmacokinetic properties of the partner drugs in artemisinin-containing combination therapies are the most important determinants of treatment outcome, particularly the maximum killing rate. We discuss the assumptions made in such modeling approaches and how similar approaches may be refined in future work.
authors.affiliation: Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L5 3QA, United Kingdom. hastings@liverpool.ac.uk.
authors.forename: Katherine
authors.initials: K
authors.lastname: Winter
authors.forename: Ian M
authors.initials: IM
authors.lastname: Hastings
mesh_terms: D000962:Antimalarials / Q000627:therapeutic use*; D037621:Artemisinins / Q000627:therapeutic use; D006801:Humans; D008288:Malaria / Q000188:drug therapy*; D008962:Models, Theoretical
chemical_list: D000962:Antimalarials; D037621:Artemisinins; C031327:artemisinin